RCi175
EDi014-A
General
Cell Line |
|
hPSCreg name | EDi014-A |
Cite as: | EDi014-A (RRID:CVCL_LE68) |
Alternative name(s) |
RCi175
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | |
Last update | 10th March 2020 |
User feedback | |
Provider |
|
Generator | University of Edinburgh (ED) |
Distributors | |
External Databases |
|
BioSamples | SAMEA4459369 |
Cellosaurus | CVCL_LE68 |
EBiSC | EDi014-A |
Wikidata | Q54831996 |
General Information |
|
Publications | |
Projects | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Family history | From multiple affected family multiple affected by bipolar and major depressive disorder |
Donor Relations |
|
Other cell lines of this donor | |
All cell lines of this donor's relatives | |
External Databases (Donor) |
|
BioSamples | SAMEA4459370 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | No |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | Andrew McIntosh |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | Yes |
Details on restriction to research project | mental and other brain disorders |
Does consent permit unforeseen future research, without further consent? | Yes |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly prevent development of commercial products? | No |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
a non-profit company? | Yes |
a for-profit corporation? | Yes |
Does consent expressly permit collection of genetic information? | Yes |
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Does consent permit access to medical records of the donor? | No |
Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Scotland A Research Ethics Committee |
Approval number | 09/MRE00/81 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Scotland A Research Ethics Committee |
Approval number | 09/MRE00/81 |
Do you have obligations to third parties in regard to the use of the cell line? | Yes |
Please describe: | Mental illness and other brain disorders |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Restricted to research into mental illness and other brain disorders. User agrees not to make an attempt to identify the original donors of the material without the expressly written permission. User agrees that any genetic or genomic data it generates from the use of the material will be held securely and only used in research as stated above. |
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
Source cell type |
Any skin fibroblast that is part of some dermis.
|
Source cell origin |
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Genes | |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
Essential 8™
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SSEA-4 |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
No autosomal or sex chromosome aneuploidies were detected
Passage number: 18
Karyotyping method:
Bacs-on-Beads
|
Other Genotyping (Cell Line) |
|
Is there genome-wide genotyping or functional data available? |
Yes
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755 This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768 |
Login to share your feedback, experiences or results with the research community.